NY-ESTÉE-LAUDER
30.9.2022 12:46:43 CEST | Business Wire | Press release
In the 30 years since Evelyn H. Lauder launched The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) and co-created the Pink Ribbon in 1992, The Campaign’s mission to help create a breast cancer-free world for all has remained steadfast. The Estée Lauder Companies (ELC) has a long-standing commitment to helping women and girls achieve their highest potential. As ELC’s largest corporate social impact program, The Campaign is a cornerstone of ELC’s social investments in women’s advancement and health, uniting people everywhere to positively impact the global breast cancer community. As breast cancer is the most commonly diagnosed cancer in the world,1 ELC's continued commitment to improving the lives of all those touched by the disease remains unwavering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005040/en/
The Estée Lauder Companies Launches 2022 Breast Cancer Campaign (Graphic: Business Wire)
Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $108 million globally for lifesaving research, education and medical services, with more than $86 million funding medical research grants through the Breast Cancer Research Foundation (BCRF). Founded in 1993 by Evelyn H. Lauder, BCRF is dedicated to advancing the world’s most promising research. ELC’s commitment to breast cancer research, spanning three decades, has been transformative. In partnership with BCRF, The Campaign has helped fuel research across the entire spectrum of the disease—from tumor biology, lifestyle and genetics, survivorship, treatment, and metastasis—making an indelible mark in the diagnosis, care, and prevention of breast cancer. In addition, The Campaign supports more than 60 organizations worldwide, facilitating real change aligned to the diverse needs of local communities.
Deaths from breast cancer have declined 42% in the U.S. since the late 1980s.2 However, that progress has not been experienced equally and certain populations are at higher risk for adverse breast cancer outcomes. At every age, Black women in the U.S. are more likely to die from breast cancer than any other race or ethnic group, and mortality rates remain 41% higher than in white women, despite lower incidence.3 The Campaign has and continues to support BCRF-funded research that identifies and addresses disparities that exist across the entire breast cancer landscape. ELCCF’s $15 million donation over five years will fund a new BCRF research initiative to accelerate The Campaign’s goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities, and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. It will help advance personalized breast cancer health care across prevention, diagnosis, and treatment for those at most risk of dying from the disease, and has the potential to be groundbreaking for the global breast cancer community.
William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc. shared, “The potential impact that this BCRF initiative will have in accelerating a crucial area of research cannot be overstated, as we collectively work towards a more equitable future for all. I know my mother, Evelyn Lauder, would be so proud of the advancements we have made through research, education, access to care and our commitment to help end breast cancer.”
In the past 30 years globally, The Campaign has:
- Funded medical research and fellowships, as well as medical resources, services and centers, including access to mammograms and screenings for vulnerable groups with limited access to healthcare.
- Advanced conversations on the importance of breast health education and early detection by facilitating discussions between the breast cancer community, medical experts and key opinion leaders.
- Supported therapy and counseling programs to help improve the lives of people with breast cancer and their families.
- Distributed educational materials and more than 180 million Pink Ribbons to spread awareness.
“The Estée Lauder Companies’ success is deeply rooted in living our shared values. Reflecting on the last 30 years, the incredible progress made by The Breast Cancer Campaign has had a lasting impact on our global community. As an authentic cornerstone of our commitments, The Campaign has been supported by our employees, consumers and partners worldwide. Today, it continues to inspire action in people everywhere. As a Beauty Inspired, Values Driven company, we look forward to the future and are committed to advancing positive change for all of those touched by this disease,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc.
The Campaign will take the following actions aligned to its mission for its 30th Anniversary:
- Double-down on The Campaign’s efforts to reduce breast cancer disparities and improve health outcomes.
- Mobilize ELC’s passionate employees to unite in action and support more than 60 organizations worldwide.
- Show support through 18 of ELC’s brands: Estée Lauder, Clinique, Lab Series, Origins, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, and Dr.Jart+. Each will donate to BCRF and/or local cancer-focused organizations around the world, with brand participation varying by market.
- Convene breast cancer thought leaders and advocates to advance education and share important messages about the disease.
- Drive additional donations to BCRF through ELCompanies.com/BreastCancerCampaign and various points of engagement.
- Accelerate communications on social media including TikTok and various Meta platforms to foster awareness, fundraising and engagement, including new calls-to-action.
- Unveil a new series of global stories demonstrating the diversity of the disease.
- Continue The Campaign’s tradition of illuminating buildings, monuments and landmarks around the world in glowing pink lights to raise awareness of breast health, including the Empire State Building, New York City; the Eiffel Tower, Paris; LOTTE WORLD TOWER, Seoul.
- Continue producing and distributing informative materials and Pink Ribbons worldwide.
As long as breast cancer remains a life-threatening disease, The Estée Lauder Companies’ commitment to the meaningful work that must continue will not waiver. It’s #TimeToEndBreastCancer.
ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-I
_____________________________
1 World Health Organization
2 American Cancer Society® Facts and Figures 2021-2022
3 American Cancer Society® Key Statistics for Breast Cancer
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220930005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification26.3.2026 06:13:00 CET | Press release
IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). Commercial availability of the IVDR-certified assay is anticipated by early April 2026. The IVDR replaces the former In Vitro Diagnostics Directive (IVDD), introducing significantly more stringent requirements for clinical evidence, performance evaluation, traceability, and post-market surveillance. Under IVDR, in vitro diagnostic devices are classified according to risk from Class A (lowest risk) to Class D (highest risk). Class C devices, such as IdentiClone Dx IGH, are considered high-risk tests that play a critical role in disease diagnosis an
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
